Subscribe
shutterstock_1662839302_tada_images
Tada Images / Shutterstock.com
24 March 2022GenericsAlex Baldwin

Novo Nordisk and Sandoz settle Victoza patent suit

Novo Nordisk and Sandoz have settled an ongoing patent dispute over the blockbuster diabetes treatment Victoza (Liraglutide) before the companies were meant to face trial in April.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
Novo Nordisk seeks to block Mylan generic
22 August 2019   Danish pharmaceutical company Novo Nordisk has sued Mylan in a US court over a proposed generic of diabetes drug Victoza (liraglutide).
Americas
Teva enters settlement with Novo Nordisk to sell Victoza generic
19 March 2019   Danish pharmaceutical company Novo Nordisk and generics maker Teva have reached a settlement in their US dispute over Victoza.
Americas
Novo Nordisk makes $1.1bn bid for biopharma company
2 September 2022   Massachusetts-based target company specialises in rare blood disorders | Deal gives Novo Nordisk access to lead development candidate, etavopivat.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Generics
Novo Nordisk seeks to block Mylan generic
22 August 2019   Danish pharmaceutical company Novo Nordisk has sued Mylan in a US court over a proposed generic of diabetes drug Victoza (liraglutide).
Americas
Teva enters settlement with Novo Nordisk to sell Victoza generic
19 March 2019   Danish pharmaceutical company Novo Nordisk and generics maker Teva have reached a settlement in their US dispute over Victoza.
Americas
Novo Nordisk makes $1.1bn bid for biopharma company
2 September 2022   Massachusetts-based target company specialises in rare blood disorders | Deal gives Novo Nordisk access to lead development candidate, etavopivat.

More on this story

Generics
Novo Nordisk seeks to block Mylan generic
22 August 2019   Danish pharmaceutical company Novo Nordisk has sued Mylan in a US court over a proposed generic of diabetes drug Victoza (liraglutide).
Americas
Teva enters settlement with Novo Nordisk to sell Victoza generic
19 March 2019   Danish pharmaceutical company Novo Nordisk and generics maker Teva have reached a settlement in their US dispute over Victoza.
Americas
Novo Nordisk makes $1.1bn bid for biopharma company
2 September 2022   Massachusetts-based target company specialises in rare blood disorders | Deal gives Novo Nordisk access to lead development candidate, etavopivat.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York